+357 96 030922
info@marketpublishers.com

Urokinase Market Forecasts to 2032 – Global Analysis By Type (Urokinase Powder and Urokinase Solution), Source, Route of Administration, Application, End User and By Geography

https://marketpublishers.com/r/U2B3550C29A8EN.html
Date: May 2025
Pages: 150
Price: US$ 4,150.00 (Single User License)
ID: U2B3550C29A8EN

Abstracts

According to Stratistics MRC, the Global Urokinase Market is accounted for $2.08 billion in 2025 and is expected to reach $3.50 billion by 2032 growing at a CAGR of 7.7% during the forecast period. Urokinase is a thrombolytic enzyme used medically to dissolve blood clots in the body. It is a serine protease originally derived from human urine, but now commonly produced using recombinant DNA technology. Urokinase works by converting plasminogen to plasmin, an enzyme that breaks down fibrin, the primary protein component of blood clots. It is primarily used to treat conditions such as pulmonary embolism, deep vein thrombosis, and catheter blockages. As a fibrinolytic agent, urokinase plays a vital role in restoring blood flow in occluded vessels, making it a critical therapeutic option in emergency and interventional medicine.

According to 2024 article by British Heart Foundation, 7.6 million people are living in with heart and circulatory disease in UK.

Market Dynamics:

Driver:

Rising Prevalence of Thrombotic Disorders

The growing incidence of thrombotic disorders is propelling the urokinase market due to the heightened need for thrombolytic treatments. The enzyme urokinase, which is employed to break down blood clots, plays a vital role in the treatment of conditions like

pulmonary embolism, deep vein thrombosis, and acute myocardial infarction. As the global prevalence of these disorders rises, particularly among aging populations, the demand for effective clot-dissolving treatments is increasing. This trend is benefiting the urokinase market and spurring further developments in its production and application.

Restraint:

High Treatment Costs

High treatment costs significantly hinder the growth of the urokinase market by limiting accessibility for patients and healthcare providers, particularly in low#- #and middle-income regions. These elevated expenses reduce the adoption of urokinase-based therapies, as more affordable alternatives are sought. Additionally, high costs strain healthcare budgets, discourage insurance coverage, and restrict widespread clinical use, ultimately slowing market expansion and impeding innovation in thrombolytic treatments.

Opportunity:

Technological Advancements in Drug Delivery

Technological advancements in drug delivery systems have significantly impacted the Urokinase market by enhancing its therapeutic efficacy and precision. Innovations such as targeted delivery mechanisms and nanoparticle-based formulations ensure better bioavailability and reduced side effects. These advancements improve the drug’s ability to target specific sites, optimizing the treatment of conditions like blood clots and heart attacks. Additionally, controlled release technologies and personalized drug delivery systems contribute to improved patient outcomes, driving demand and growth within the Urokinase market.

Threat:

Risk of Bleeding Complications

The risk of bleeding complications significantly hinders the growth of the urokinase market. Urokinase, a thrombolytic agent, carries a high potential for causing internal bleeding, particularly in patients with underlying conditions or on anticoagulants. This safety concern limits its widespread adoption among healthcare providers, prompting cautious prescription practices. Additionally, regulatory restrictions and the availability of safer alternatives further restrain market expansion, negatively impacting demand and overall market performance.

Covid-19 Impact

The COVID-19 pandemic significantly disrupted the urokinase market due to delays in elective surgeries, reduced hospital admissions, and supply chain interruptions. Demand for non-COVID-related therapies, including thrombolytic agents like urokinase, declined during the peak of the pandemic. However, as healthcare systems stabilized and surgical procedures resumed, the market began recovering. Additionally, increased awareness of thrombotic complications in COVID-19 patients indirectly supported demand for anticoagulant and thrombolytic therapies.

The urokinase solution segment is expected to be the largest during the forecast period

The urokinase solution segment is expected to account for the largest market share during the forecast period because Urokinase solutions, particularly in intravenous and local delivery forms, are gaining preference due to their ability to rapidly dissolve blood clots, improving patient outcomes in conditions like pulmonary embolism and deep vein thrombosis. The growing adoption of urokinase solutions in hospitals and healthcare facilities, combined with ongoing research, is further fueling the segment's positive impact on market expansion.

The deep vein thrombosis segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the deep vein thrombosis segment is predicted to witness the highest growth rate, due to the rising incidence of thrombotic disorders and increased awareness of early diagnosis and treatment. Urokinase, a thrombolytic agent, is widely used to dissolve blood clots in DVT patients, leading to its growing demand. Advancements in healthcare infrastructure and an aging population further contribute to market expansion. This trend positions DVT as a key driver fueling sustained growth and innovation in the urokinase market.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share due to rising cardiovascular cases, increased awareness, and improved access to advanced therapies are driving demand. This growth is fostering innovation, encouraging investments, and improving patient outcomes across developing nations. Additionally, government support and expanding healthcare infrastructure are accelerating market penetration, making life-saving thrombolytic therapies more accessible, ultimately contributing to better public health and a stronger regional pharmaceutical landscape.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, owing to increasing awareness of thrombolytic therapies. Advancements in healthcare infrastructure, strong presence of key pharmaceutical players, and supportive regulatory frameworks further fuel market expansion. The growing geriatric population and demand for minimally invasive procedures enhance the uptake of urokinase-based treatments. Collectively, these factors are significantly improving patient outcomes and driving the regional market’s growth and innovation.

Key players in the market

Some of the key players profiled in the Urokinase Market include Syner-Med Ltd., Microbix Biosystems Inc., Wuxi Green Pharmaceutical Co., Ltd., Jiangxi Haoran Bio-Pharma Co., Ltd., Medicure Inc., Lee's Pharmaceutical Holdings Ltd., Taj Pharmaceuticals Limited, Jiangsu Techpool Bio-Pharma Co., Ltd., Guangzhou Recomgen Biotech Co., Ltd., LGM Pharma, ScienCell Research Laboratories, Inc., BioVision, Inc., Abbott Laboratories, Enzo Life Sciences, Inc., Molecular Innovations, Inc., Prospec-Tany Technogene Ltd., Wuhan YZY Biopharma Co., Ltd., GenScript Biotech Corporation and Chymotech AS.

Key Developments:

In August 2024, Abbott and Medtronic announced a significant global partnership, to integrate Abbott's FreeStyle Libre continuous glucose monitoring (CGM) technology with Medtronic's insulin delivery systems. This collaboration aims to enhance diabetes management by enabling automatic insulin adjustments based on real-time glucose data.

In June 2024, Abbott has partnered with the National Association of Community Health Centers (NACHC) to improve access to nutritious food and health services. The collaboration aims to enhance healthcare delivery and address the growing health challenges related to nutrition in underserved communities.

Types Covered:

- Urokinase Powder
- Urokinase Solution

Sources Covered:

- Human-derived Urokinase
- Recombinant Urokinase

Routes of Administration Covered:

- Intravenous
- Intracatheter

Applications Covered:

- Pulmonary Embolism
- Deep Vein Thrombosis
- Catheter Occlusion
- Myocardial Infarction
- Other Application

End Users Covered:

- Hospitals

+357 96 030922
info@marketpublishers.com

Specialty Clinics

Ambulatory Surgical Centers

Other End Users

Regions Covered:

North America

US

Canada

Mexico

Europe

Germany

UK

Italy

France

Spain

Rest of Europe

Asia Pacific

Japan

China

India

Australia

New Zealand

South Korea

Rest of Asia Pacific

South America

Argentina

Brazil

Chile

Rest of South America

Middle East & Africa

Saudi Arabia

UAE

Qatar

South Africa

Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations

- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

Company Profiling

Comprehensive profiling of additional market players (up to 3)

SWOT Analysis of key players (up to 3)

Regional Segmentation

Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)

Competitive Benchmarking

Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

+357 96 030922
info@marketpublishers.com

Contents

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

List Of Tables

LIST OF TABLES

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

Table 125 Middle East & Africa Urokinase Market Outlook, By Ambulatory Surgical Centers (2024-2032) ($MN)
Table 126 Middle East & Africa Urokinase Market Outlook, By Other End Users (2024-2032) ($MN)

+357 96 030922
info@marketpublishers.com

I would like to order

Product name: Urokinase Market Forecasts to 2032 – Global Analysis By Type (Urokinase Powder and Urokinase Solution), Source, Route of Administration, Application, End User and By Geography

Product link: https://marketpublishers.com/r/U2B3550C29A8EN.html

Price: US$ 4,150.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/U2B3550C29A8EN.html